L-DOS47 combines Helix’s proprietary DOS47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung.
John Docherty, president of Helix, said: “This new arrangement advances the company closer to its objective of initiating clinical testing with L-DOS47. The lyophilized packaging format will provide for optimum stability of L-DOS47 while in storage so that individual vials may be reconstituted in liquid form immediately prior to patient administration.”